To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment
June 24, 2019 at 10:04 AM EDT
The sale of Celgene's Otezla will "allow the transaction to close on a timely basis," Bristol-Myers Squibb said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|